Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 101 articles: HTML format

Single Articles

November 2025
1. MAMDANI H, Gentzler RD, Gu L, Chiappori AA, et al
   A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.
   Cancer. 2025;131:e70141.
   PubMed     Abstract available
   
   
   October 2025
2. ISLAMI F, Wiese D, Schafer EJ, Sung H, et al
   Stage-specific cancer survival in Black and White persons by urbanicity of county of residence, United States, 2015-2021.
   Cancer. 2025;131:e70073.
   PubMed     Abstract available
   
   
   
3. NIERENGARTEN MB
   Therapies for patients with previously treated lung cancer: Two second-line therapies receive accelerated approval for treatment.
   Cancer. 2025;131:e70076.
   PubMed    
   
   
   September 2025
4. FATHI JT, Cinciripini PM, DePrimo MJ, Houston TP, et al
   The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening.
   Cancer. 2025;131:e35972.
   PubMed     Abstract available
   
   
   
5. COOPER AJ, Garbo E, Arfe A, Conroy M, et al
   Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
   Cancer. 2025;131:e70081.
   PubMed     Abstract available
   
   
   
6. FLOREZ N, Patel S, Wakelee HA, Rotow J, et al
   Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.
   Cancer. 2025;131:e70060.
   PubMed     Abstract available
   
   
   
7. VOLK RJ, Lettieri JS, Leal VB, Duhon GF, et al
   The quality of patient decision aids for lung cancer screening: Results from an environmental scan.
   Cancer. 2025;131:e70008.
   PubMed     Abstract available
   
   
   
8. HUANG L, Zeng F, Huang P, Ren D, et al
   Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.
   Cancer. 2025;131:e70063.
   PubMed     Abstract available
   
   
   August 2025
9. OLSON JMG, Knight JR, Copeland AM, Ohlander KA, et al
   The American Cancer Society National Lung Cancer Roundtable strategic plan: Addressing planning for lung cancer interventions at the state and local level through the creation of the National Lung Cancer Roundtable Planning Tool.
   Cancer. 2025;131:e35954.
   PubMed     Abstract available
   
   
   
10. STUDTS JL, Carter-Bawa L, Hamann HA, Smith RA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Changing the lung cancer story: Addressing survivorship, stigma, and nihilism to facilitate transformation.
    Cancer. 2025;131:e35969.
    PubMed     Abstract available
    
    
    
11. HOWLADER N, Cronin KA, Yu M, Miller D, et al
    Urban-rural disparities in lung cancer incidence and mortality patterns in Black and White populations.
    Cancer. 2025;131:e70004.
    PubMed     Abstract available
    
    
    
12. NIERENGARTEN MB
    Effective and efficient large-scale lung cancer screening: Low-dose computed tomography screening for lung cancer enables early diagnosis in asymptomatic, high-risk individuals and has been shown to reduce lung cancer-related mortality.
    Cancer. 2025;131:e35956.
    PubMed    
    
    
    July 2025
13. BROWN LM, Wilkins SG, Bansal VV, Su DG, et al
    Consensus guideline for the management of peritoneal mesothelioma.
    Cancer. 2025;131:e35868.
    PubMed     Abstract available
    
    
    June 2025
14. LEAL TA, Wang Y, Dowlati A, Chay CH, et al
    Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
    Cancer. 2025;131:e35938.
    PubMed     Abstract available
    
    
    
15. PASSIGLIA F, Pepe F, Russo G, Garbo E, et al
    Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer.
    Cancer. 2025;131:e35917.
    PubMed     Abstract available
    
    
    May 2025
16. DENNEHY C, Conroy MR, Forde PM
    Immunotherapy for resectable lung cancer.
    Cancer. 2025;131:e35849.
    PubMed     Abstract available
    
    
    
17. KILICKAP S, Ozguroglu M, Sezer A, Gumus M, et al
    Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 >/=50.
    Cancer. 2025;131:e35864.
    PubMed     Abstract available
    
    
    
18. HOFF CO, Feng L, Bonini F, Sousa LG, et al
    Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma.
    Cancer. 2025;131:e35901.
    PubMed     Abstract available
    
    
    
19. SHOU J, Chen J, Guo Q, Hong W, et al
    Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial.
    Cancer. 2025;131:e35822.
    PubMed     Abstract available
    
    
    
20. GARG SK, Kohli K, Garg IK, Garg YK, et al
    Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
    Cancer. 2025;131:e35903.
    PubMed     Abstract available
    
    
    
21. HARRIS AK, Nelson AT, Watson D, Mallinger PHR, et al
    Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.
    Cancer. 2025;131:e35862.
    PubMed     Abstract available
    
    
    
22. THOMAS QD, Vendrell JA, Khellaf L, Cavaillon S, et al
    Artificial intelligence-driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer.
    Cancer. 2025;131:e35882.
    PubMed     Abstract available
    
    
    April 2025
23. MACHIDA N, Okumura T, Boku N, Kishimoto J, et al
    A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G).
    Cancer. 2025;131:e35807.
    PubMed     Abstract available
    
    
    March 2025
24. SHIELDS MD, Chiang AC, Byers LA
    Top advances of the year: Small cell lung cancer.
    Cancer. 2025;131:e35770.
    PubMed     Abstract available
    
    
    
25. BOGDANSKA W, Paik PK
    From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping.
    Cancer. 2025;131 Suppl 1:e35782.
    PubMed     Abstract available
    
    
    
26. JIMENEZ MUNARRIZ BE, Khan S, Li Y, Ghazali N, et al
    Update advances in anaplastic lymphoma kinase-positive non-small cell lung cancer treatment.
    Cancer. 2025;131 Suppl 1:e35786.
    PubMed     Abstract available
    
    
    
27. SHAVERDASHVILI K, Burns TF
    Advances in the treatment of KRAS(G12C) mutant non-small cell lung cancer.
    Cancer. 2025;131 Suppl 1:e35783.
    PubMed     Abstract available
    
    
    
28. PARISI C, Planchard D
    BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice.
    Cancer. 2025;131 Suppl 1:e35781.
    PubMed     Abstract available
    
    
    
29. HOE HJ, Solomon BJ
    Treatment of non-small cell lung cancer with RET rearrangements.
    Cancer. 2025;131 Suppl 1:e35779.
    PubMed     Abstract available
    
    
    
30. KIM J, Park S, Ku BM, Ahn MJ, et al
    Updates on the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer.
    Cancer. 2025;131 Suppl 1:e35778.
    PubMed     Abstract available
    
    
    
31. REINHORN D, Moskovitz M, Tap WD, Li BT, et al
    Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies.
    Cancer. 2025;131 Suppl 1:e35780.
    PubMed     Abstract available
    
    
    
32. DESILETS A, Repetto M, Yang SR, Drilon A, et al
    Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions.
    Cancer. 2025;131 Suppl 1:e35784.
    PubMed     Abstract available
    
    
    February 2025
33. SANDS JM, Champiat S, Hummel HD, Paulson KG, et al
    Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
    Cancer. 2025;131:e35738.
    PubMed     Abstract available
    
    
    January 2025
34. NIERENGARTEN MB
    First person profile: Julie Brahmer, MD: Dr Brahmer's research paved the way for the first immunotherapy agent to receive US Food and Drug Administration approval for the treatment of lung cancer.
    Cancer. 2025;131:e35686.
    PubMed    
    
    
    
35. PASSMAN JE, Kallan MJ, Roberson JL, Ginzberg SP, et al
    Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies.
    Cancer. 2025;131:e35664.
    PubMed     Abstract available
    
    
    
36. GANTI AK, Fruth B, Rimner A, Waqar S, et al
    Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance.
    Cancer. 2025;131:e35663.
    PubMed     Abstract available
    
    
    
37. MCCOLL KS, Ajay A, Wang H, Wildey GM, et al
    Identification of HEPACAM2 as a novel and specific marker of small cell carcinoma.
    Cancer. 2025;131:e35557.
    PubMed     Abstract available
    
    
    December 2024
38. POTTER AL, Kuhan S, Senthil P, Mansur A, et al
    The 2021 US Preventive Services Task Force lung cancer screening eligibility criteria disproportionately exclude younger Black patients with lung cancer.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35676.
    PubMed     Abstract available
    
    
    
39. ZHANG D, Rohatgi A
    Improving survival for patients with metastatic non-small cell lung cancer in the immunotherapy era.
    Cancer. 2024 Dec 11. doi: 10.1002/cncr.35675.
    PubMed    
    
    
    November 2024
40. DESAI P, Zhou Y, Grenet J, Handelman SK, et al
    Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.
    Cancer. 2024;130:3879-3887.
    PubMed     Abstract available
    
    
    October 2024
41. NIERENGARTEN MB
    Durvalumab not cost-effective with current pricing strategies for stage III NSCLC: The drug remains inaccessible to many patients for whom it is indicated as a standard of care after chemoradiation.
    Cancer. 2024;130:3236.
    PubMed    
    
    
    September 2024
42. FOX AH, Osarogiagbon RU, Farjah F, Jett JR, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non-small cell lung cancer.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34628.
    PubMed     Abstract available
    
    
    
43. FARJAH F, Barta JA, Wood DE, Rivera MP, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Promoting guideline-concordant lung cancer staging.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34627.
    PubMed     Abstract available
    
    
    
44. ROY-CHOWDHURI S, Mani H, Fox AH, Tsao A, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.34926.
    PubMed     Abstract available
    
    
    
45. BARTA JA, Farjah F, Thomson CC, Dyer DS, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Optimizing strategies for lung nodule evaluation and management.
    Cancer. 2024 Sep 30. doi: 10.1002/cncr.35181.
    PubMed     Abstract available
    
    
    
46. BACKHUS LM, Chang CF, Sakoda LC, Chambers SR, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Lung cancer in women.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.35083.
    PubMed     Abstract available
    
    
    
47. FATHI JT, Barry AM, Greenburg GM, Henschke CI, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Implementation of high-quality lung cancer screening.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.34621.
    PubMed     Abstract available
    
    
    
48. LEWIS JA, Klein DE, Eberth JM, Carter-Bawa L, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Provider engagement and outreach.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.34555.
    PubMed     Abstract available
    
    
    
49. VOLK RJ, Myers RE, Arenberg D, Caverly TJ, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Current challenges and future directions for shared decision making for lung cancer screening.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.35382.
    PubMed     Abstract available
    
    
    
50. KAZEROONI EA, Wood DE, Rosenthal LS, Smith RA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Introduction.
    Cancer. 2024 Sep 20. doi: 10.1002/cncr.35385.
    PubMed     Abstract available
    
    
    
51. NIERENGARTEN MB
    ASCO 2024: Advances in lung cancer treatments and care: A new standard of care therapy based on the results of the LAURA study underscores the need for testing for epidermal growth factor receptor (EGFR) mutations in patients with unresectable stage I
    Cancer. 2024;130:2894.
    PubMed    
    
    
    August 2024
52. NIERENGARTEN MB
    First person profile: Heather A. Wakelee, MD: For more than 20 years, she has served in multiple functions, including developing research programs in lung cancer and thymoma that include clinical trials and population science approaches.
    Cancer. 2024;130:2730.
    PubMed    
    
    
    
53. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
    Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
    Cancer. 2024;130:2770-2781.
    PubMed     Abstract available
    
    
    July 2024
54. WANG Y, Kondrat K, Adhikari J, Nguyen Q, et al
    Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database-based study.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35476.
    PubMed     Abstract available
    
    
    June 2024
55. CHO H, Kwon H, Kim SH, Ahn HM, et al
    Seasonal influences on the efficacy of anti-programmed cell death (ligand) 1 inhibitors in lung cancer.
    Cancer. 2024 Jun 28. doi: 10.1002/cncr.35454.
    PubMed     Abstract available
    
    
    
56. MAKAREM M, Janne PA
    Top advances of the year: Targeted therapy for lung cancer.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35423.
    PubMed     Abstract available
    
    
    
57. YABROFF KR, Mittu K, Halpern MT
    Cost-of-care discussions for individuals with advanced non-small cell lung cancer and melanoma: Findings from a large, population-based pilot study.
    Cancer. 2024 Jun 13. doi: 10.1002/cncr.35380.
    PubMed     Abstract available
    
    
    
58. EDWARDS DM, Pirzadeh M, Van T, Jiang R, et al
    Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancer.
    Cancer. 2024 Jun 10. doi: 10.1002/cncr.35340.
    PubMed     Abstract available
    
    
    
59. BYUN JY, Aiyeolemi A, Qdaisat A, Park C, et al
    Association between epidermal growth factor receptor-tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non-small cell lung cancer.
    Cancer. 2024 Jun 7. doi: 10.1002/cncr.35424.
    PubMed     Abstract available
    
    
    May 2024
60. AREDO JV, Wakelee HA
    Top advances of the year: Perioperative therapy for lung cancer.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35357.
    PubMed     Abstract available
    
    
    
61. LEAL TA, Ramalingam SS
    Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35353.
    PubMed    
    
    
    
62. YOUNG LK, Halmos B
    Immunotherapy for metastatic non-small cell lung cancer: Is it really a no-brainer?
    Cancer. 2024 May 6. doi: 10.1002/cncr.35350.
    PubMed    
    
    
    April 2024
63. AJABNOOR AM, Parisi R, Zghebi SS, Ashcroft DM, et al
    Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019.
    Cancer. 2024;130:1316-1329.
    PubMed     Abstract available
    
    
    March 2024
64. VITA E, Monaca F, Milardi D, Mastrantoni L, et al
    Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer.
    Cancer. 2024 Mar 28. doi: 10.1002/cncr.35293.
    PubMed     Abstract available
    
    
    
65. WISNIVESKY JP, Mudd J, Stone K, Slatore CG, et al
    Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Cancer. 2024 Mar 21. doi: 10.1002/cncr.35286.
    PubMed     Abstract available
    
    
    
66. CITTOLIN-SANTOS GF, Knapp B, Ganesh B, Gao F, et al
    The changing landscape of small cell lung cancer.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35281.
    PubMed     Abstract available
    
    
    
67. NIERENGARTEN MB
    Updated American Cancer Society lung cancer screening guidelines: The new guidelines offer expanded criteria recommended for lung cancer screening based on age, smoking status, and smoking history.
    Cancer. 2024;130:656-657.
    PubMed    
    
    
    
68. WEST HJ, Pennell NA
    Lessons from ADAURA: Can we improve on a positive trial?
    Cancer. 2024;130:659-664.
    PubMed    
    
    
    February 2024
69. TAN AC, Lai GGY, Saw SPL, Chua KLM, et al
    Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35263.
    PubMed     Abstract available
    
    
    
70. MORGENSZTERN D
    The expanding role of circulating tumor DNA in resectable non-small cell lung cancer.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35268.
    PubMed    
    
    
    
71. 
    Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study".
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165.
    PubMed    
    
    
    
72. NIERENGARTEN MB
    Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy-based treatment for NSCLC.
    Cancer. 2024;130:495-496.
    PubMed    
    
    
    
73. DESAI A, Smith CJ, Pritchett JC, Leventakos K, et al
    Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC).
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35250.
    PubMed     Abstract available
    
    
    
74. ZHOU Y, Guo T, Liang F, Wang Z, et al
    Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242.
    PubMed     Abstract available
    
    
    
75. RUSSELL AM, Pack AP, Bailey SC, Weldon CB, et al
    A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35240.
    PubMed    
    
    
    January 2024
76. IOCOLANO M, Yegya-Raman N, Friedes C, Wang X, et al
    Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
    Cancer. 2024 Jan 31. doi: 10.1002/cncr.35230.
    PubMed     Abstract available
    
    
    
77. FLOREZ N, Kaufman RA, Yanez-Sarmiento A, Abioye O, et al
    When the unimaginable happens: Lung cancer diagnosis during pregnancy.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35227.
    PubMed    
    
    
    
78. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    PubMed     Abstract available
    
    
    
79. KRATZER TB, Bandi P, Freedman ND, Smith RA, et al
    Lung cancer statistics, 2023.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35128.
    PubMed     Abstract available
    
    
    
80. ROLFO C, Del Re M, Russo A
    Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers.
    Cancer. 2024 Jan 18. doi: 10.1002/cncr.35203.
    PubMed    
    
    
    
81. HONG J, Lee J, Park S, Jung HA, et al
    Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
    Cancer. 2024 Jan 2. doi: 10.1002/cncr.35175.
    PubMed     Abstract available
    
    
    
82. MEZA R, Cao P, de Nijs K, Jeon J, et al
    Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: A simulation modeling study.
    Cancer. 2024;130:244-255.
    PubMed     Abstract available
    
    
    December 2023
83. TRAN TN, Lee S, Kim HJ, Lee Y, et al
    Treatment-related cardiovascular events in patients with non-small cell lung cancer: Evidence from real-world data with a competing risks approach.
    Cancer. 2023 Dec 16. doi: 10.1002/cncr.35143.
    PubMed     Abstract available
    
    
    
84. WANG S, Xie T, Li Y, Guo L, et al
    Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
    Cancer. 2023;129:3873-3883.
    PubMed     Abstract available
    
    
    
85. ZHAO X, Yang M, Fan J, Wang M, et al
    Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.
    Cancer. 2023 Dec 6. doi: 10.1002/cncr.35130.
    PubMed     Abstract available
    
    
    
86. 
    Immunotherapy plus stereotactic radiation therapy improves event-free survival in early-stage non-small cell lung cancer.
    Cancer. 2023;129:3680.
    PubMed    
    
    
    November 2023
87. GUAN MC, Ding Q, Ning J, Zhu H, et al
    Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus.
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35111.
    PubMed    
    
    
    
88. LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al
    Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus".
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35134.
    PubMed    
    
    
    
89. GRIESINGER F, Ramagopalan S, Cheung WY, Wilke T, et al
    Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.
    Cancer. 2023 Nov 7. doi: 10.1002/cncr.35094.
    PubMed     Abstract available
    
    
    
90. LANDY R, Cheung LC, Young CD, Chaturvedi AK, et al
    Absolute lung cancer risk increases among individuals with >15 quit-years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34758.
    PubMed     Abstract available
    
    
    
91. HENDRICK RE, Smith RA
    Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34855.
    PubMed     Abstract available
    
    
    October 2023
92. VAN VEGGEL BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, et al
    A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
    Cancer. 2023 Oct 31. doi: 10.1002/cncr.35090.
    PubMed     Abstract available
    
    
    
93. MAHAR AL, Biggs K, Hansford RL, Derksen S, et al
    Stage IV breast, colorectal, and lung cancer at diagnosis in adults living with intellectual or developmental disabilities: A population-based cross-sectional study.
    Cancer. 2023 Oct 30. doi: 10.1002/cncr.35068.
    PubMed     Abstract available
    
    
    
94. CHOI E, Luo SJ, Ding VY, Wu JT, et al
    Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
    Cancer. 2023 Oct 25. doi: 10.1002/cncr.35069.
    PubMed     Abstract available
    
    
    
95. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    PubMed     Abstract available
    
    
    
96. FLOREZ N, Kiel L, Meza K, Wei Z, et al
    Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35057.
    PubMed     Abstract available
    
    
    
97. VAN TUIJL LA, Basten M, Pan KY, Vermeulen R, et al
    Depression, anxiety, and the risk of cancer: An individual participant data meta-analysis.
    Cancer. 2023;129:3287-3299.
    PubMed     Abstract available
    
    
    
98. 
    Erratum to "JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer".
    Cancer. 2023 Oct 13. doi: 10.1002/cncr.35064.
    PubMed    
    
    
    
99. TAMMEMAGI MC, Cina K, Kitts AKB, Koop D, et al
    Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Cancer. 2023 Oct 9. doi: 10.1002/cncr.34947.
    PubMed     Abstract available
    
    
    September 2023
100. LU S, Guo X, Li Y, Liu H, et al
     Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
     Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003.
     PubMed     Abstract available
     
     
     
101. TAMMEMAGI MC
     Time to quit using quit time as a lung cancer screening eligibility criterion.
     Cancer. 2023 Sep 1. doi: 10.1002/cncr.34999.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.